|
1
|
Dickersin GR, Kline IW and Scully RE:
Small cell carcinoma of the ovary with hypercalcemia: A report of
eleven cases. Cancer. 49:188–197. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ulbright TM, Roth LM, Stehman FB, Talerman
A and Senekjian EK: Poorly differentiated (small cell) carcinoma of
the ovary in young women: Evidence supporting a germ cell origin.
Hum Pathol. 18:175–184. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McCluggage WG, Oliva E, Connolly LE,
McBride HA and Young RH: An immunohistochemical analysis of ovarian
small cell carcinoma of hypercalcemic type. Int J Gynecol Pathol.
23:330–336. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jelinic P, Mueller JJ, Olvera N, Dao F,
Scott SN, Shah R, Gao J, Schultz N, Gonen M, Soslow RA, et al:
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
Nat Genet. 46:424–426. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Witkowski L, Carrot-Zhang J, Albrecht S,
Fahiminiya S, Hamel N, Tomiak E, Grynspan D, Saloustros E, Nadaf J,
Rivera B, et al: Germline and somatic SMARCA4 mutations
characterize small cell carcinoma of the ovary, hypercalcemic type.
Nat Genet. 46:438–443. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ramos P, Karnezis AN, Craig DW, Sekulic A,
Russell ML, Hendricks WP, Corneveaux JJ, Barrett MT, Shumansky K,
Yang Y, et al: Small cell carcinoma of the ovary, hypercalcemic
type, displays frequent inactivating germline and somatic mutations
in SMARCA4. Nat Genet. 46:427–429. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karnezis AN, Wang Y, Ramos P, Hendricks
WP, Oliva E, D’Angelo E, Prat J, Nucci MR, Nielsen TO, Chow C, et
al: Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and
SMARCA2/BRM is highly sensitive and specific for small cell
carcinoma of the ovary, hypercalcaemic type. J Pathol. 238:389–400.
2016. View Article : Google Scholar :
|
|
8
|
Kadoch C, Hargreaves DC, Hodges C, Elias
L, Ho L, Ranish J and Crabtree GR: Proteomic and bioinformatic
analysis of mammalian SWI/SNF complexes identifies extensive roles
in human malignancy. Nat Genet. 45:592–601. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Foulkes WD, Clarke BA, Hasselblatt M,
Majewski J, Albrecht S and McCluggage WG: No small surprise - small
cell carcinoma of the ovary, hypercalcaemic type, is a malignant
rhabdoid tumour. J Pathol. 233:209–214. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Witkowski L, Goudie C, Foulkes WD and
McCluggage WG: Small-cell carcinoma of the ovary of hypercalcemic
type (malignant rhabdoid tumor of the ovary): A review with recent
developments on pathogenesis. Surg Pathol Clin. 9:215–226. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Johann PD, Erkek S, Zapatka M, Kerl K,
Buchhalter I, Hovestadt V, Jones DT, Sturm D, Hermann C, Segura
Wang M, et al: Atypical teratoid/rhabdoid tumors are comprised of
three epigenetic subgroups with distinct enhancer landscapes.
Cancer Cell. 29:379–393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Witkowski L, Goudie C, Ramos P, Boshari T,
Brunet JS, Karnezis AN, Longy M, Knost JA, Saloustros E, McCluggage
WG, et al: The influence of clinical and genetic factors on patient
outcome in small cell carcinoma of the ovary, hypercalcemic type.
Gynecol Oncol. 141:454–460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Otte A, Göhring G, Steinemann D,
Schlegelberger B, Groos S, Länger F, Kreipe HH, Schambach A,
Neumann T, Hillemanns P, et al: A tumor-derived population
(SCCOHT-1) as cellular model for a small cell ovarian carcinoma of
the hypercalcemic type. Int J Oncol. 41:765–775. 2012.PubMed/NCBI
|
|
14
|
Gamwell LF, Gambaro K, Merziotis M, Crane
C, Arcand SL, Bourada V, Davis C, Squire JA, Huntsman DG, Tonin PN,
et al: Small cell ovarian carcinoma: Genomic stability and
responsiveness to therapeutics. Orphanet J Rare Dis. 8:332013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pittenger MF, Mackay AM, Beck SC, Jaiswal
RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and
Marshak DR: Multilineage potential of adult human mesenchymal stem
cells. Science. 284:143–147. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Caplan AI: Why are MSCs therapeutic? New
data: New insight. J Pathol. 217:318–324. 2009. View Article : Google Scholar
|
|
17
|
Hass R, Kasper C, Böhm S and Jacobs R:
Different populations and sources of human mesenchymal stem cells
(MSC): A comparison of adult and neonatal tissue-derived MSC. Cell
Commun Signal. 9:122011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bianco P: ‘Mesenchymal’ stem cells. Annu
Rev Cell Dev Biol. 30:677–704. 2014. View Article : Google Scholar
|
|
19
|
Friedl P and Alexander S: Cancer invasion
and the microenvironment: Plasticity and reciprocity. Cell.
147:992–1009. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ungefroren H, Sebens S, Seidl D, Lehnert H
and Hass R: Interaction of tumor cells with the microenvironment.
Cell Commun Signal. 9:182011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hass R and Otte A: Mesenchymal stem cells
as all-round supporters in a normal and neoplastic
microenvironment. Cell Commun Signal. 10:262012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Karnoub AE, Dash AB, Vo AP, Sullivan A,
Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg
RA: Mesenchymal stem cells within tumour stroma promote breast
cancer metastasis. Nature. 449:557–563. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mandel K, Yang Y, Schambach A, Glage S,
Otte A and Hass R: Mesenchymal stem cells directly interact with
breast cancer cells and promote tumor cell growth in vitro and in
vivo. Stem Cells Dev. 22:3114–3127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Y, Otte A and Hass R: Human
mesenchymal stroma/stem cells exchange membrane proteins and alter
functionality during interaction with different tumor cell lines.
Stem Cells Dev. 24:1205–1222. 2015. View Article : Google Scholar :
|
|
25
|
Yang Y, Bucan V, Baehre H, von der Ohe J,
Otte A and Hass R: Acquisition of new tumor cell properties by
MSC-derived exosomes. Int J Oncol. 47:244–252. 2015.PubMed/NCBI
|
|
26
|
Upchurch KS, Parker LM, Scully RE and
Krane SM: Differential cyclic AMP responses to calcitonin among
human ovarian carcinoma cell lines: a calcitonin-responsive line
derived from a rare tumor type. J Bone Miner Res. 1:299–304. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang Y, Melzer C, Bucan V, von der Ohe J,
Otte A and Hass R: Conditioned umbilical cord tissue provides a
natural three-dimensional storage compartment as in vitro stem cell
niche for human mesenchymal stroma/stem cells. Stem Cell Res Ther.
7:282016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Otte A, Rauprich F, von der Ohe J, Yang Y,
Kommoss F, Feuerhake F, Hillemanns P and Hass R: c-Met inhibitors
attenuate tumor growth of small cell hypercalcemic ovarian
carcinoma (SCCOHT) populations. Oncotarget. 6:31640–31658.
2015.PubMed/NCBI
|
|
29
|
Otte A, Rauprich F, Hillemanns P,
Park-Simon TW, von der Ohe J and Hass R: In vitro and in vivo
therapeutic approach for a small cell carcinoma of the ovary
hypercalcaemic type using a SCCOHT-1 cellular model. Orphanet J
Rare Dis. 9:1262014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsikitis M, Zhang Z, Edelman W, Zagzag D
and Kalpana GV: Genetic ablation of Cyclin D1 abrogates genesis of
rhabdoid tumors resulting from Ini1 loss. Proc Natl Acad Sci USA.
102:12129–12134. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mazaud Guittot S, Vérot A, Odet F, Chauvin
MA and le Magueresse-Battistoni B: A comprehensive survey of the
laminins and collagens type IV expressed in mouse Leydig cells and
their regulation by LH/hCG. Reproduction. 135:479–488. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lu F, Ma FF, Zhang W, Li Y, Wei FY and
Zhou L: Qualitative research of alternatively splice variants of
fibronectin in different development stage of mice heart. J Thorac
Dis. 7:2307–2312. 2015.
|
|
33
|
Zillhardt M, Park SM, Romero IL, Sawada K,
Montag A, Krausz T, Yamada SD, Peter ME and Lengyel E: Foretinib
(GSK1363089), an orally available multikinase inhibitor of c-Met
and VEGFR-2, blocks proliferation, induces anoikis, and impairs
ovarian cancer metastasis. Clin Cancer Res. 17:4042–4051. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Parr C and Jiang WG: Expression of
hepatocyte growth factor/scatter factor, its activator, inhibitors
and the c-Met receptor in human cancer cells. Int J Oncol.
19:857–863. 2001.PubMed/NCBI
|
|
35
|
Montesinos JJ, Mora-García ML, Mayani H,
Flores-Figueroa E, García-Rocha R, Fajardo-Orduña GR,
Castro-Manrreza ME, Weiss-Steider B and Monroy-García A: In vitro
evidence of the presence of mesenchymal stromal cells in cervical
cancer and their role in protecting cancer cells from cytotoxic T
cell activity. Stem Cells Dev. 22:2508–2519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lis R, Touboul C, Halabi NM, Madduri AS,
Querleu D, Mezey J, Malek JA, Suhre K and Rafii A: Mesenchymal cell
interaction with ovarian cancer cells induces a background
dependent prometastatic transcriptomic profile. J Transl Med.
12:592014. View Article : Google Scholar
|
|
37
|
Melzer C, Yang Y and Hass R: Interaction
of MSC with tumor cells. Cell Commun Signal. 14:202016. View Article : Google Scholar : PubMed/NCBI
|
